CDK12 Activates MYC to Repress miR-28-5p/EZH2 and Amplifies Tonic BCR Signaling to Promote the Development of Diffuse Large B Cell Lymphoma

Cyclin-dependent kinase 12 (CDK12) activated MYC to repress miR-28-5p/EZH2 and amplified tonic BCR signaling to promote the development of diffuse large B cell lymphoma (DLBCL), which might provide potential therapeutic targets for future therapeutic intervention in DLBCL.